"HLA-A2 Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A specific HLA-A surface antigen subtype. Members of this subtype contain alpha chains that are encoded by the HLA-A*02 allele family.
| Descriptor ID |
D015789
|
| MeSH Number(s) |
D12.776.395.550.489.400.020 D12.776.543.550.439.400.020 D23.050.301.500.100.400.020 D23.050.301.500.450.370.020 D23.050.705.552.100.400.020 D23.050.705.552.450.370.374
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "HLA-A2 Antigen".
Below are MeSH descriptors whose meaning is more specific than "HLA-A2 Antigen".
This graph shows the total number of publications written about "HLA-A2 Antigen" by people in this website by year, and whether "HLA-A2 Antigen" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
| 2004 | 1 | 1 | 2 |
| 2005 | 0 | 1 | 1 |
| 2006 | 0 | 2 | 2 |
| 2008 | 0 | 1 | 1 |
| 2009 | 1 | 0 | 1 |
| 2010 | 1 | 0 | 1 |
| 2011 | 0 | 2 | 2 |
| 2015 | 2 | 0 | 2 |
| 2019 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "HLA-A2 Antigen" by people in Profiles.
-
Final analysis of a phase I/IIa trial of the folate-binding protein-derived E39 peptide vaccine to prevent recurrence in ovarian and endometrial cancer patients. Cancer Med. 2019 08; 8(10):4678-4687.
-
Human Leukocyte Antigen-Presented Macrophage Migration Inhibitory Factor Is a Surface Biomarker and Potential Therapeutic Target for Ovarian Cancer. Mol Cancer Ther. 2016 Feb; 15(2):313-22.
-
Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science. 2015 May 15; 348(6236):803-8.
-
An HLA-presented fragment of macrophage migration inhibitory factor is a therapeutic target for invasive breast cancer. J Immunol. 2011 Jun 01; 186(11):6607-16.
-
Although divergent in residues of the peptide binding site, conserved chimpanzee Patr-AL and polymorphic human HLA-A*02 have overlapping peptide-binding repertoires. J Immunol. 2011 Feb 01; 186(3):1575-88.
-
Single-chain HLA-A2 MHC trimers that incorporate an immundominant peptide elicit protective T cell immunity against lethal West Nile virus infection. J Immunol. 2010 Apr 15; 184(8):4423-30.
-
Amyloid precursor-like protein 2 association with HLA class I molecules. Cancer Immunol Immunother. 2009 Sep; 58(9):1419-31.
-
Identification of breast cancer peptide epitopes presented by HLA-A*0201. J Proteome Res. 2008 Apr; 7(4):1445-57.
-
Development and implementation of a direct detection, quantitation and validation system for class I MHC self-peptide epitopes. J Immunol Methods. 2007 Jan 10; 318(1-2):47-58.
-
Critical factors in the development of fluorescence polarization-based peptide binding assays: an equilibrium study monitoring specific peptide binding to soluble HLA-A*0201. J Immunol Methods. 2006 Jul 31; 314(1-2):38-53.